{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:44:11Z","timestamp":1780109051503,"version":"3.54.0"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T00:00:00Z","timestamp":1479427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Oral cannabis extracts (<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>s) are being used in the treatment of epilepsy with increasing rates in the United States following product legalization; however, no studies demonstrate clear efficacy. We evaluated the duration of use of<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>s as a measure of perceived benefit in a cohort of patients with pediatric epilepsy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective chart review was performed of children and adolescents who were given<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>s for treatment of epilepsy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 119 patients included in the analysis, 71% terminated use of their<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>product during the study period. The average length of use of<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>was 11.7 months (range 0.3\u201357 months). Perceived seizure benefit was the only factor associated with longer duration of treatment with<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>(p &lt; 0.01). Relocation to Colorado was associated with perceived benefit of<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>s for seizures (65% vs. 38%, p = 0.01), but was not independently associated with longer<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>use. Factors associated with shorter use included adverse effects (p = 0.03) and a diagnosis of Dravet syndrome (p = 0.02). Twenty\u2010four percent of patients were considered<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>responders, which was defined by a parent's report of a &gt; 50% reduction in seizures while on this therapy. Adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s) were reported in 19% of patients, with the most common side effects being somnolence and worsening of seizures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>Parental report of<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>use in refractory pediatric epilepsy suggests that some families perceive benefit from this therapy; however, discontinuation of these products is common. Duration appears to be affected by logical factors, such as perceived benefit and side effect profile. Surprisingly, families of patients with Dravet syndrome terminated use of<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>s more quickly than patients with other epilepsy syndromes. Results from this study highlight the need for rigorous clinical studies to characterize the efficacy and safety of<jats:styled-content style=\"fixed-case\">OCE<\/jats:styled-content>s, which can inform discussions with patients and families.<\/jats:p><\/jats:sec>","DOI":"10.1111\/epi.13617","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T11:53:09Z","timestamp":1479469989000},"page":"123-127","source":"Crossref","is-referenced-by-count":43,"title":["Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients"],"prefix":"10.1111","volume":"58","author":[{"given":"Lauren","family":"Treat","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Neurology Children's Hospital Colorado Anschutz Medical Campus University of Colorado Aurora Colorado U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin E.","family":"Chapman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Neurology Children's Hospital Colorado Anschutz Medical Campus University of Colorado Aurora Colorado U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Colborn","sequence":"additional","affiliation":[{"name":"Division of Health Care Policy and Research and ACCORDS Anschutz Medical Campus University of Colorado Aurora Colorado U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly G.","family":"Knupp","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Neurology Children's Hospital Colorado Anschutz Medical Campus University of Colorado Aurora Colorado U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.04.009"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2013.08.037"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0022-3565(25)30824-4","article-title":"Cannabidiol\u2013antiepileptic drug comparisons and interactions in experimentally induced seizures in rats","volume":"201","author":"Consroe P","year":"1977","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13060"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.159145"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1407304"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02523.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2012.03.001"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(82)90418-X"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.08.135"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00379-8"},{"key":"e_1_2_8_13_1","first-page":"CD009270","article-title":"Cannabinoids for epilepsy","volume":"6","author":"Gloss D","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000446"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318212ab0c"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-5050(02)00687-X"},{"key":"e_1_2_8_17_1","unstructured":"Available at:https:\/\/www.colorado.gov\/pacific\/cdphe\/data. Accessed June 3 2016."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.02.043"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsq114"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000115653.82763.07"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0139-z"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.12.002"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01946.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182635735"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318232de76"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2012.03.010"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.13617","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.13617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T18:47:33Z","timestamp":1749754053000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.13617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/epi.13617"],"URL":"https:\/\/doi.org\/10.1111\/epi.13617","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,18]]}}}